NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies ID3950

Provisional Stakeholder List

Consultees	**Commentators (no right to submit or appeal)**
Company • Novartis (tisagenlecleucel) Patient/carer groups • African Caribbean Leukaemia Trust • Anthony Nolan • Black Health Agency for Equality • Blood Cancer UK • Cancer Black Care • Cancer Equality • Cancer52 • DKMS • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Lymphoma Action • Macmillan Cancer Support • Maggie's Centres • Marie Curie • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • WMUK Healthcare Professional groups • Association of Cancer Physicians • British Association of Dermatologists • British Committee for Standards in Haematology • British Dermatological Nursing Group • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Haematology • Cancer Research UK	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Possible comparator companies • Accord (bendamustine, fludarabine) • Aspen (chlorambucil) • Baxter Healthcare (cyclophosphamide) • Dr Reddy's (bendamustine) • Gilead (axicabtagene ciloleucel) • Napp Phamaceuticals (rituximab) • Pfizer (rituximab) • Roche (mosunetuzumab, obinutuzumab, rituximab) • Sandoz (cyclophosphamide, rituximab) • Sanofi (fludarabine)

Consultees	**Commentators (no right to submit or appeal)**
• Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Cutaneous Lymphoma Group • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS England • NHS Erewash CCG • NHS Haringey CCG • Welsh Government	• Seacross Pharmaceuticals (bendamustine) • Zentiva (bendamustine) <u>Relevant research groups</u> • British Epidermo-Epidemiology Society • Cochrane Haematological Malignancies Group • Cochrane Skin Group • Cochrane UK • Genomics England • Institute of Cancer Research • Leukaemia UK • Leukaemia Busters • Lymphoma Research Trust • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research <u>Associated Public Health Groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.

